| # | Title | Journal | Year | Citations |
|---|
| 1 | Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota | Science | 2015 | 2,539 |
| 2 | 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) | Annals of Oncology | 2018 | 891 |
| 3 | CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner | Journal of Experimental Medicine | 2005 | 806 |
| 4 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) | Annals of Oncology | 2020 | 761 |
| 5 | ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach | Annals of Oncology | 2019 | 614 |
| 6 | Cutaneous side-effects of kinase inhibitors and blocking antibodies | Lancet Oncology, The | 2005 | 527 |
| 7 | Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriers | Journal of Medical Genetics | 2015 | 479 |
| 8 | Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial | Lancet Oncology, The | 2014 | 434 |
| 9 | The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial | Cancer Discovery | 2018 | 397 |
| 10 | Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma | Annals of Oncology | 2010 | 379 |
| 11 | Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg | European Journal of Cancer | 2005 | 351 |
| 12 | Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment | Annals of Surgical Oncology | 2009 | 334 |
| 13 | Management of hypertension in angiogenesis inhibitor-treated patients | Annals of Oncology | 2009 | 305 |
| 14 | Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas | JAMA Oncology | 2018 | 303 |
| 15 | Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Nature Medicine | 2020 | 282 |
| 16 | Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 | Annals of Oncology | 2021 | 279 |
| 17 | VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management | European Journal of Cancer | 2010 | 277 |
| 18 | ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research | Annals of Oncology | 2019 | 263 |
| 19 | Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future | Lancet, The | 2020 | 260 |
| 20 | Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis | Lancet Oncology, The | 2019 | 247 |
| 21 | Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic Effect | Annals of Surgical Oncology | 2005 | 240 |
| 22 | High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients | Annals of Oncology | 2012 | 239 |
| 23 | The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer | European Journal of Cancer | 2012 | 237 |
| 24 | Radiotherapy for renal-cell carcinoma | Lancet Oncology, The | 2014 | 226 |
| 25 | Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer | Annals of Oncology | 2010 | 216 |
| 26 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2012 | 216 |
| 27 | Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience | Annals of Surgical Oncology | 2013 | 190 |
| 28 | Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought | Annals of Surgical Oncology | 2013 | 187 |
| 29 | Nasopharyngeal carcinomas | European Journal of Cancer | 2003 | 182 |
| 30 | An attempt to clarify indications for hepatectomy for liver metastases from breast cancer | American Journal of Surgery | 2003 | 175 |
| 31 | Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer | Clinical Cancer Research | 2013 | 173 |
| 32 | Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients | Annals of Oncology | 2013 | 172 |
| 33 | Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO) | Oncologist | 2012 | 170 |
| 34 | ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours | British Journal of Cancer | 2004 | 166 |
| 35 | Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results | European Urology | 2018 | 164 |
| 36 | Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma | | 2000 | 156 |
| 37 | Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies | European Journal of Cancer | 2010 | 150 |
| 38 | Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study | Annals of Oncology | 2018 | 150 |
| 39 | Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma | European Urology | 2019 | 138 |
| 40 | Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial | Annals of Oncology | 2016 | 133 |
| 41 | Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis | Lancet Oncology, The | 2019 | 131 |
| 42 | A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas | European Journal of Cancer | 2012 | 129 |
| 43 | Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin | Annals of Surgical Oncology | 2007 | 125 |
| 44 | ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease | European Urology | 2011 | 125 |
| 45 | Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases | | 1998 | 122 |
| 46 | The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma | European Journal of Cancer | 2004 | 122 |
| 47 | Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer | Cell Reports | 2012 | 122 |
| 48 | Impact of surgical staging in patients with macroscopic “stage I” ovarian borderline tumours: analysis of a continuous series of 101 cases | European Journal of Cancer | 2004 | 119 |
| 49 | Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement | Annals of Oncology | 2013 | 117 |
| 50 | Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes | Clinical Cancer Research | 2014 | 117 |
